Teva Pharmaceutical Industries annual revenue
2007
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Revenue Growth & History (TEVA)
Teva Pharmaceutical Industries reported $17.26B in revenue for fiscal 2025, an increase of 4.32% from the previous fiscal year.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.26B | $714.0M | +4.32% |
| 2024 | 2024-12-31 | $16.54B | $698.0M | +4.40% |
| 2023 | 2023-12-31 | $15.85B | $921.0M | +6.17% |
| 2022 | 2022-12-31 | $14.93B | −$953.0M | −6.00% |
| 2021 | 2021-12-31 | $15.88B | −$781.0M | −4.69% |
| 2020 | 2020-12-31 | $16.66B | −$228.0M | −1.35% |
| 2019 | 2019-12-31 | $16.89B | −$1.38B | −7.57% |
| 2018 | 2018-12-31 | $18.27B | −$3.58B | −16.39% |
| 2017 | 2017-12-31 | $21.85B | −$50.0M | −0.23% |
| 2016 | 2016-12-31 | $21.90B | — | — |
| 2013 | 2013-12-31 | $20.31B | −$3.0M | −0.01% |
| 2012 | 2012-12-31 | $20.32B | $2.00B | +10.95% |
| 2011 | 2011-12-31 | $18.31B | $2.19B | +13.59% |
| 2010 | 2010-12-31 | $16.12B | $0 | 0.00% |
| 2009 | 2009-12-31 | $16.12B | $5.04B | +45.43% |
| 2008 | 2008-12-31 | $11.09B | $1.68B | +17.83% |
| 2007 | 2007-12-31 | $9.41B | — | — |
Teva Pharmaceutical Industries quarterly revenue
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.14B | −$34.0M | −0.81% |
| Q1 2026 | 2026-03-31 | $3.98B | $91.0M | +2.34% |
| Q4 2025 | 2025-12-31 | $1.50B | −$2.73B | −64.53% |
| Q3 2025 | 2025-09-30 | $4.48B | $148.0M | +3.42% |
| Q2 2025 | 2025-06-30 | $4.18B | $12.0M | +0.29% |
| Q1 2025 | 2025-03-31 | $3.89B | $72.0M | +1.89% |
| Q4 2024 | 2024-12-31 | $4.23B | −$228.0M | −5.12% |
| Q3 2024 | 2024-09-30 | $4.33B | $482.0M | +12.52% |
| Q2 2024 | 2024-06-30 | $4.16B | $286.0M | +7.37% |
| Q1 2024 | 2024-03-31 | $3.82B | $158.0M | +4.32% |
| Q4 2023 | 2023-12-31 | $4.46B | $574.0M | +14.78% |
| Q3 2023 | 2023-09-30 | $3.85B | $255.0M | +7.09% |
| Q2 2023 | 2023-06-30 | $3.88B | $92.0M | +2.43% |
| Q1 2023 | 2023-03-31 | $3.66B | $0 | 0.00% |
| Q4 2022 | 2022-12-31 | $3.88B | −$216.0M | −5.27% |
| Q3 2022 | 2022-09-30 | $3.60B | −$292.0M | −7.51% |
| Q2 2022 | 2022-06-30 | $3.79B | −$124.0M | −3.17% |
| Q1 2022 | 2022-03-31 | $3.66B | −$321.0M | −8.06% |
| Q4 2021 | 2021-12-31 | $4.10B | −$355.0M | −7.97% |
| Q3 2021 | 2021-09-30 | $3.89B | −$91.0M | −2.29% |
| Q2 2021 | 2021-06-30 | $3.91B | $40.0M | +1.03% |
| Q1 2021 | 2021-03-31 | $3.98B | −$375.0M | −8.61% |
| Q4 2020 | 2020-12-31 | $4.45B | −$14.0M | −0.31% |
| Q3 2020 | 2020-09-30 | $3.98B | −$115.0M | −2.81% |
| Q2 2020 | 2020-06-30 | $3.87B | −$307.0M | −7.35% |
| Q1 2020 | 2020-03-31 | $4.36B | $208.0M | +5.01% |
| Q4 2019 | 2019-12-31 | $4.47B | $49.0M | +1.11% |
| Q3 2019 | 2019-09-30 | $4.09B | −$292.0M | −6.66% |
| Q2 2019 | 2019-06-30 | $4.18B | −$375.0M | −8.24% |
| Q1 2019 | 2019-03-31 | $4.15B | −$767.0M | −15.60% |
| Q4 2018 | 2018-12-31 | $4.42B | −$979.0M | −18.14% |
| Q3 2018 | 2018-09-30 | $4.38B | −$1.23B | −21.93% |
| Q2 2018 | 2018-06-30 | $4.55B | −$1.17B | −20.42% |
| Q1 2018 | 2018-03-31 | $4.92B | −$734.0M | −12.99% |
| Q4 2017 | 2017-12-31 | $5.40B | −$1.09B | −16.85% |
| Q3 2017 | 2017-09-30 | $5.62B | $54.0M | +0.97% |
| Q2 2017 | 2017-06-30 | $5.72B | $682.0M | +13.54% |
| Q1 2017 | 2017-03-31 | $5.65B | $840.0M | +17.46% |
| Q4 2016 | 2016-12-31 | $6.49B | — | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $5.56B | $740.0M | +15.34% |
| Q2 2016 · Jun 30 | 2016-06-30 | $5.04B | $72.0M | +1.45% |
| Q1 2016 · Mar 31 | 2016-03-31 | $4.81B | −$172.0M | −3.45% |
| Q3 2016 · Sep 30 | 2015-09-30 | $4.82B | −$235.0M | −4.65% |
| Q2 2016 · Jun 30 | 2015-06-30 | $4.97B | −$79.0M | −1.57% |
| Q1 2016 · Mar 31 | 2015-03-31 | $4.98B | −$19.0M | −0.38% |
| Q3 2014 | 2014-09-30 | $5.06B | −$1.0M | −0.02% |
| Q2 2014 | 2014-06-30 | $5.04B | $121.0M | +2.46% |
| Q1 2014 | 2014-03-31 | $5.00B | $100.0M | +2.04% |
| Q4 2013 | 2013-12-31 | $5.43B | $73.0M | +1.36% |
| Q3 2013 | 2013-09-30 | $5.06B | $87.0M | +1.75% |
| Q2 2013 | 2013-06-30 | $4.92B | −$70.0M | −1.40% |
| Q1 2013 | 2013-03-31 | $4.90B | −$93.0M | −1.86% |
| Q4 2012 | 2012-12-31 | $5.36B | −$319.0M | −5.62% |
| Q3 2012 | 2012-09-30 | $4.97B | $628.0M | +14.46% |
| Q2 2012 | 2012-06-30 | $4.99B | $782.0M | +18.57% |
| Q1 2012 | 2012-03-31 | $4.99B | $914.0M | +22.40% |
| Q4 2011 | 2011-12-31 | $5.68B | $1.26B | +28.47% |
| Q3 2011 | 2011-09-30 | $4.34B | $94.0M | +2.21% |
| Q2 2011 | 2011-06-30 | $4.21B | $412.0M | +10.84% |
| Q1 2011 | 2011-03-31 | $4.08B | $427.0M | +11.69% |
| Q4 2010 | 2010-12-31 | $4.42B | −$1.61B | −26.66% |
| Q3 2010 | 2010-09-30 | $4.25B | $700.0M | +19.72% |
| Q2 2010 | 2010-06-30 | $3.80B | $400.0M | +11.76% |
| Q1 2010 | 2010-03-31 | $3.65B | $506.0M | +16.08% |
| Q4 2009 | 2009-12-31 | $6.02B | $3.18B | +111.52% |
| Q3 2009 | 2009-09-30 | $3.55B | $708.0M | +24.91% |
| Q2 2009 | 2009-06-30 | $3.40B | $577.0M | +20.44% |
| Q1 2009 | 2009-03-31 | $3.15B | $575.0M | +22.36% |
| Q4 2008 | 2008-12-31 | $2.85B | — | — |
| Q3 2008 | 2008-09-30 | $2.84B | — | — |
| Q2 2008 | 2008-06-30 | $2.82B | — | — |
| Q1 2008 | 2008-03-31 | $2.57B | — | — |
Teva Pharmaceutical Industries revenue growth trends
Over the last five reported fiscal years, revenue grew from $16.66B to $17.26B, a compound annual growth rate of 0.71%. Teva Pharmaceutical Industries's latest reported quarter, Q2 2026, generated $4.14B in revenue, a decrease of 0.81% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Teva Pharmaceutical Industries source filings ↗